SERPINH1 is a Potential Prognostic Biomarker and Correlated With Immune Infiltration: A Pan-Cancer Analysis

Area of Science:

• Oncology
• Genetics
• Immunology

Background:

• Serpin peptidase inhibitor clade H, member 1 (SERPINH1) is implicated in poor prognosis for several cancers.
• The pan-cancer role of SERPINH1 remains largely uninvestigated.

Purpose of the Study:

• To explore the expression and prognostic significance of SERPINH1 across diverse human cancers.
• To investigate the association of SERPINH1 with tumor mutation burden, DNA methylation, and immune infiltration.

Main Methods:

• Analysis of SERPINH1 expression and survival data from The Cancer Genome Atlas and Genotype-Tissue Expression datasets.
• Correlation analyses for tumor mutation burden (TMB), microsatellite instability (MSI), mismatch repair (MMR), DNA methylation, and immune markers.
• Assessment of immune cell infiltration using the Tumor Immune Evaluation Resource database and immunohistochemistry validation.

Main Results:

• SERPINH1 exhibited abnormal expression in fourteen cancer types, with high expression linked to reduced overall survival in eleven.
• SERPINH1 expression correlated with MMR, MSI, TMB, and DNA methylation across multiple cancers.
• Significant associations were found between SERPINH1 and immunoregulators, immune checkpoints, and immune cell infiltration, particularly in specific cancer types like LGG and breast cancer.

Conclusions:

• SERPINH1 serves as a potential prognostic biomarker in pan-cancer.
• SERPINH1 expression is significantly associated with tumor immunity and could influence cancer progression.